Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for Malaria Chemoprophylaxis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Malaria Chemoprophylaxis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on Malaria Chemoprophylaxis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Chemoprophylaxis and intermittent treatment for preventing malaria in children. Malaria causes repeated illness in children living in endemic areas. Policies of giving antimalarial drugs at regular intervals (prophylaxis or intermittent treatment) are being considered for preschool children.To evaluate prophylaxis and intermittent treatment with antimalarial drugs to prevent malaria in young children living in malaria-endemic areas.We searched the Cochrane Infectious Diseases Group Specialized (...) Register (August 2007), CENTRAL (The Cochrane Library 2007, Issue 3), MEDLINE (1966 to August 2007), EMBASE (1974 to August 2007), LILACS (1982 to August 2007), mRCT (February 2007), and reference lists of identified trials. We also contacted researchers.Individually randomized and cluster-randomized controlled trials comparing antimalarial drugs given at regular intervals (prophylaxis or intermittent treatment) with placebo or no drug in children aged one month to six years or less living in a malaria
The efficacy of malariachemoprophylaxis The efficacy of malariachemoprophylaxis The efficacy of malariachemoprophylaxis Saridi M, Vasiliki P, Saroglou G CRD summary The authors concluded that atovaquone/proguanil, tafenoquine, primaquine were the most effective regimens for malariachemoprophylaxis, but tafenoquine and primaquine should not be prescribed to individuals with G6PD deficiency. Given the limitations of the review data and concerns about the methodology and reporting (...) , Saroglou G. The efficacy of malariachemoprophylaxis. Health Science Journal 2008; 2(1): 3-14 Indexing Status Subject indexing assigned by CRD MeSH Aminoquinolines /therapeutic use; Antimalarials /therapeutic use; Atovaquone /therapeutic use; Chemoprevention; Communicable Disease Control; Malaria /prevention & Primaquine /therapeutic use; control AccessionNumber 12008105102 Date bibliographic record published 03/02/2009 Date abstract record published 13/01/2010 Record Status This is a critical abstract
Reimbursement of malariachemoprophylaxis for travellers from Europe to Sub-Saharan Africa: cost-effectiveness analysis from the perspective of the French national health insurance system Reimbursement of malariachemoprophylaxis for travellers from Europe to Sub-Saharan Africa: cost-effectiveness analysis from the perspective of the French national health insurance system Reimbursement of malariachemoprophylaxis for travellers from Europe to Sub-Saharan Africa: cost-effectiveness analysis (...) compared the cost-effectiveness of reimbursing malariachemoprophylaxis at a rate of 65% against the usual strategy of no reimbursement, for French residents who occasionally travelled to Sub-Saharan Africa. The authors concluded that 65% reimbursement was a cost-effective strategy from the perspective of the French national health insurance system. The analysis had several limitations and the reporting, especially for the effectiveness data, was insufficient. The authors’ conclusions should be treated
Controversies and misconceptions in malariachemoprophylaxis for travelers. Controversies in malaria prevention arise from the absence of data, conflicting data between different studies, conflicting recommendations, deviation of local practice from scientific data, and varying risk thresholds. Misconceptions about the seriousness of malaria, the tolerability of chemoprophylaxis drugs, and the efficacy and safety of repellents contribute to the controversies.To compare several national (...) guidelines on malariachemoprophylaxis to identify variations in recommendations. We reviewed studies on tolerability of mefloquine with particular focus on its neuropsychiatric adverse effects and influence on performance. We also describe why most recommended chemoprophylactic regimens fail to prevent relapses of Plasmodium vivax malaria and review available options.We searched scientific publications in MEDLINE via PubMED for relevant articles with a cutoff date of December 2006 using the search terms
A systematic review and meta-analysis of the effectiveness and safety of atovaquone-proguanil (Malarone) for chemoprophylaxis against malaria Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Malariachemoprophylaxis in sickle cell disease. Malaria is the most common precipitating cause of crises in sickle cell disease in malaria-endemic countries. Health professionals often recommend life-long malariachemoprophylaxis for people with sickle cell disease living in these areas. It is therefore important we have good evidence of benefit.To assess the effects of routine malariachemoprophylaxis in people with sickle cell disease.We searched the Cochrane Infectious Diseases Group (...) 0.04 to 0.83; 97 children), hospital admissions (RR 0.27, 95% CI 0.12 to 0.63; 97 participants), and blood transfusions (RR 0.16, 95% CI 0.05 to 0.56; 97 participants). A quasi-randomized controlled trial of 126 children in Uganda compared an antimalarial drug plus antibiotics with no antimalarial plus placebo. Chemoprophylaxis reduced the number of episodes of malaria and dactylitis, and increased mean haemoglobin values in this trial.It is beneficial to give routine malariachemoprophylaxis
Malaria intermittent preventive treatment in infants, chemoprophylaxis, and childhood vaccinations. Malaria accounts for 1-3 million deaths yearly worldwide, mostly in children under 5 years of age in sub-Saharan Africa. Laboratory and clinical studies show an association between acute malaria and a decreased response to diphtheria and tetanus toxoids and to meningococcal, salmonella, and Haemophilus influenzae type b vaccinations. Malaria treatment, chemoprophylaxis, or other forms of parasite (...) with the first of three daily doses of amodiaquine intermittent preventive treatment (IPTi) or placebo. After 60 days, children receiving amodiaquine had significantly fewer malaria fevers than controls.The increasing concordance of malaria control and vaccination, movement toward co-administration of IPTi with immunisation, and the increase in travellers to malarious areas who receive concurrent vaccinations and chemoprophylaxis warrant further study.
Delayed onset of malaria--implications for chemoprophylaxis in travelers. Most antimalarial agents used by travelers act on the parasite's blood stage and therefore do not prevent late-onset illness, particularly that due to species that cause relapsing malaria. We examined the magnitude of this problem among Israeli and American travelers.We examined malaria surveillance data from Israel and the United States to determine the traveler's destination, the infecting species, the type (...) of chemoprophylaxis used, and the incubation period.In Israel, from 1994 through 1999, there were 300 cases of malaria among returning travelers in which one species of plasmodium could be identified. In 134 of these cases (44.7 percent), the illness developed more than two months after the traveler's return; nearly all of these cases were due to infection with Plasmodium vivax or P. ovale. In 108 of the 134 cases (80.6 percent), the patient had used an antimalarial regimen according to national guidelines
Tolerability of malariachemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. To compare the tolerability of malariachemoprophylaxis regimens in non-immune travellers.Randomised, double blind, study with placebo run-in phase.Travel clinics in Switzerland, Germany, and Israel.Proportion of participants in each treatment arm with subjectively moderate or severe adverse events.623 non-immune travellers to sub-Saharan Africa: 153
Cost-effectiveness of iron supplementation and malariachemoprophylaxis in the prevention of anaemia and malaria among Tanzanian infants Cost-effectiveness of iron supplementation and malariachemoprophylaxis in the prevention of anaemia and malaria among Tanzanian infants Cost-effectiveness of iron supplementation and malariachemoprophylaxis in the prevention of anaemia and malaria among Tanzanian infants Alonso Gonzalez M, Menendez C, Font F, Kahigwa E, Kimario J, Mshinda H, Tanner M, Bosch (...) -Capblanch X, Alonso P L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Iron supplementation and malariachemoprophylaxis (Deltaprim) in the prevention of anaemia and malaria. Type of intervention Primary prevention. Economic study
Malariachemoprophylaxis with tafenoquine: a randomised study. Tafenoquine is an analogue of primaquine with an improved therapeutic and safety profile. It has a long half-life and activity against liver-stage malaria parasites, so may be useful for chemoprophylaxis. In this randomised, double-blind study we assessed the efficacy and safety of tafenoquine in different doses.2144 individuals aged 12-20 years living in Lambaréné, Gabon, an endemic area for Plasmodium falciparum malaria, were (...) to replace currently used drugs for malariachemoprophylaxis.
2000LancetControlled trial quality: predicted high
Randomised placebo-controlled trial of iron supplementation and malariachemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. Malaria and anaemia, especially that due to iron deficiency, are two leading causes of morbidity worldwide. Little is known about the relative contribution of Plasmodium falciparum infection and iron deficiency to the aetiology of anaemia in malaria-endemic areas. We undertook a randomised comparison of different strategies for control (...) . supplementation was given from 8 to 24 weeks of age, and the weekly chemoprophylaxis from 8 to 48 weeks. The frequency of severe anaemia (packed-cell volume < 25%) and malaria episodes was assessed through a combination of passive case detection and cross-sectional surveys.The groups that received iron supplementation had a lower frequency of severe anaemia than those that did not receive iron (0.62 vs 0.87 cases per person-year; protective efficacy 28.8% [95% CI 6.3-45.8). Iron supplementation had no effect
1997LancetControlled trial quality: predicted high
Inadequacy of chlorproguanil 20 mg per week as chemoprophylaxis for falciparum malaria in Kenya. After treatment with chloroquine and pyrimethamine/sulfadoxine, 118 school children aged 6 to 10 years living near the Kenyan coast were enrolled in a malariachemoprophylaxis study and followed up for 20 weeks. Children were randomly assigned to receive either chlorproguanil 20 mg weekly (n = 78) or placebo (n = 37). The attack rate of Plasmodium falciparum infection was 42% in chlorproguanil